Bayer's (BAYRY.US) first-in-class new drug approved for market launch.

Wisdom Financial APP learned that recently, Bayer (BAYRY.US) announced that its elinzanetant has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of vasomotor symptoms (VMS), commonly known as hot flashes, related to menopause. Elinzanetant is the first non-hormonal neurokinin-1,3 (NK-1,3) dual receptor antagonist, and this is the first approval of the product for hot flashes globally. This approval is based on the results of three phase III clinical trials, OASIS-1, OASIS-2, and OASIS-3.